{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:44:12Z","timestamp":1789595052764,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11102-024-01485-x","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T19:12:09Z","timestamp":1738177929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Medical management pathways for Cushing\u2019s disease in pituitary tumors centers of excellence (PTCOEs)"],"prefix":"10.1007","volume":"28","author":[{"given":"A.","family":"Giustina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Uygur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Frara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Barkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. R.","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Freda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Haberbosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U. B.","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lamberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Laws","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. B.","family":"Nachtigall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Schilbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J. van der","family":"Lely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A. H.","family":"Wass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. F.","family":"Casanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"12","key":"1485_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/s2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875 Epub 2021\/10\/24. https:\/\/doi.org\/10.1016\/s2213-8587(21)00235-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1485_CR2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","volume":"43","author":"S Melmed","year":"2022","unstructured":"Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G et al (2022) Clinical Biology of the Pituitary Adenoma. Endocr Rev 43(6):1003\u20131037. https:\/\/doi.org\/10.1210\/endrev\/bnac010PubMed PMID: 35395078; PubMed Central PMCID: PMCPMC9695123","journal-title":"Endocr Rev"},{"issue":"2","key":"1485_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/cen.14014","volume":"91","author":"S Wengander","year":"2019","unstructured":"Wengander S, Trimpou P, Papakokkinou E, Ragnarsson O (2019) The incidence of endogenous Cushing\u2019s syndrome in the modern era. Clin Endocrinol (Oxf) 91(2):263\u2013270 Epub 20190527. https:\/\/doi.org\/10.1111\/cen.14014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10418","key":"1485_CR4","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/S0140-6736(23)01961-X","volume":"402","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Gatto F, Wildemberg LE, Fleseriu M (2023) Cushing\u2019s syndrome. Lancet 402(10418):2237\u20132252 Epub 20231117. doi: 10.1016\/s0140-6736(23)01961-x. PubMed PMID: 37984386","journal-title":"Lancet"},{"issue":"12","key":"1485_CR5","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1210\/jc.2003-030871","volume":"88","author":"G Arnaldi","year":"2003","unstructured":"Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP et al (2003) Diagnosis and complications of Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 88(12):5593\u20135602. https:\/\/doi.org\/10.1210\/jc.2003-030871PubMed PMID: 14671138","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1485_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.beem.2017.03.002","volume":"31","author":"AM Formenti","year":"2017","unstructured":"Formenti AM, Maffezzoni F, Doga M, Mazziotti G, Giustina A (2017) Growth hormone deficiency in treated acromegaly and active Cushing\u2019s syndrome. Best Pract Res Clin Endocrinol Metab 31(1):79\u201390 Epub 20170309. https:\/\/doi.org\/10.1016\/j.beem.2017.03.002","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"1485_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11102-021-01148-1","volume":"24","author":"S Frara","year":"2021","unstructured":"Frara S, Allora A, Castellino L, di Filippo L, Loli P, Giustina A (2021) COVID-19 and the pituitary. Pituitary 24(3):465\u2013481 Epub 20210503. https:\/\/doi.org\/10.1007\/s11102-021-01148-1","journal-title":"Pituitary"},{"issue":"2","key":"1485_CR8","doi-asserted-by":"publisher","first-page":"101515","DOI":"10.1016\/j.beem.2021.101515","volume":"35","author":"S Frara","year":"2021","unstructured":"Frara S, Allora A, di Filippo L, Formenti AM, Loli P, Polizzi E et al (2021) Osteopathy in mild adrenal Cushing\u2019s syndrome and Cushing disease. Best Pract Res Clin Endocrinol Metab 35(2):101515 Epub 20210310. https:\/\/doi.org\/10.1016\/j.beem.2021.101515","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1485_CR9","doi-asserted-by":"publisher","unstructured":"Giustina A, Wehrenberg WB (1992) The role of glucocorticoids in the regulation of Growth Hormone secretion: mechanisms and clinical significance. Trends Endocrinol Metab.;3(8):306\u2013\u200911. https:\/\/doi.org\/10.1016\/1043-2760(92)90142-n. PubMed PMID: 18407116","DOI":"10.1016\/1043-2760(92)90142-n"},{"issue":"5","key":"1485_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11892-017-0860-9","volume":"17","author":"G Mazziotti","year":"2017","unstructured":"Mazziotti G, Formenti AM, Frara S, Maffezzoni F, Doga M, Giustina A (2017) Diabetes in Cushing Disease. Curr Diab Rep 17(5):32. https:\/\/doi.org\/10.1007\/s11892-017-0860-9PubMed PMID: 28364356","journal-title":"Curr Diab Rep"},{"key":"1485_CR11","doi-asserted-by":"crossref","unstructured":"Puig-Domingo M, Marazuela M, Giustina A (2020) COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine.;68(1):2\u20135. doi: 10.1007\/s12020-020-02294-5. PubMed PMID: 32279224; PubMed Central PMCID: PMCPMC7150529","DOI":"10.1007\/s12020-020-02294-5"},{"issue":"7","key":"1485_CR12","doi-asserted-by":"publisher","first-page":"e2843","DOI":"10.1210\/clinem\/dgac183","volume":"107","author":"S Frara","year":"2022","unstructured":"Frara S, Melin Uygur M, di Filippo L, Doga M, Losa M, Santoro S et al (2022) High prevalence of vertebral fractures Associated with preoperative GH levels in patients with recent diagnosis of Acromegaly. J Clin Endocrinol Metab 107(7):e2843\u2013e50. https:\/\/doi.org\/10.1210\/clinem\/dgac183PubMed PMID: 35349698","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1485_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.tem.2011.09.001","volume":"22","author":"G Mazziotti","year":"2011","unstructured":"Mazziotti G, Gazzaruso C, Giustina A (2011) Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 22(12):499\u2013506 Epub 20111011. https:\/\/doi.org\/10.1016\/j.tem.2011.09.001","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"1485_CR14","doi-asserted-by":"publisher","first-page":"101521","DOI":"10.1016\/j.beem.2021.101521","volume":"35","author":"OA Hakami","year":"2021","unstructured":"Hakami OA, Ahmed S, Karavitaki N (2021) Epidemiology and mortality of Cushing\u2019s syndrome. Best Pract Res Clin Endocrinol Metab 35(1):101521 Epub 20210315. https:\/\/doi.org\/10.1016\/j.beem.2021.101521","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"7","key":"1485_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/s2213-8587(16)30005-5","volume":"4","author":"RN Clayton","year":"2016","unstructured":"Clayton RN, Jones PW, Reulen RC, Stewart PM, Hassan-Smith ZK, Ntali G et al (2016) Mortality in patients with Cushing\u2019s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 4(7):569\u2013576 Epub 20160602. https:\/\/doi.org\/10.1016\/s2213-8587(16)30005-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1485_CR16","doi-asserted-by":"publisher","first-page":"R227","DOI":"10.1530\/eje-14-0883","volume":"172","author":"S Petersenn","year":"2015","unstructured":"Petersenn S, Beckers A, Ferone D, van der Lely A, Bollerslev J, Boscaro M et al (2015) Therapy of endocrine disease: outcomes in patients with Cushing\u2019s disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. Eur J Endocrinol 172(6):R227\u2013R239 Epub 20150119. https:\/\/doi.org\/10.1530\/eje-14-0883","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1485_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","volume":"20","author":"FF Casanueva","year":"2017","unstructured":"Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS et al (2017) Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a Pituitary Society statement. Pituitary 20(5):489\u2013498","journal-title":"Pituitary"},{"issue":"3","key":"1485_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ecl.2020.05.010","volume":"49","author":"S Frara","year":"2020","unstructured":"Frara S, Rodriguez-Carnero G, Formenti AM, Martinez-Olmos MA, Giustina A, Casanueva FF (2020) Pituitary Tumors Centers of Excellence. Endocrinol Metab Clin North Am 49(3):553\u2013564 Epub 20200715. https:\/\/doi.org\/10.1016\/j.ecl.2020.05.010","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"1485_CR19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1007\/s11102-022-01264-6","volume":"25","author":"M Couselo","year":"2022","unstructured":"Couselo M, Frara S, Giustina A, Casanueva FF (2022) Pituitary tumor centers of excellence for Cushing\u2019s disease. Pituitary 25(5):772\u2013775 Epub 20220910. doi: 10.1007\/s11102-022-01264-6. PubMed PMID: 36087228; PubMed Central PMCID: PMCPMC9587956","journal-title":"Pituitary"},{"issue":"8","key":"1485_CR20","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO et al (2015) Treatment of Cushing\u2019s syndrome: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100(8):2807\u20132831 Epub 2015\/07\/30. https:\/\/doi.org\/10.1210\/jc.2015-1818","journal-title":"J Clin Endocrinol Metab"},{"key":"1485_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2147\/TCRM.S12952","volume":"6","author":"T Mancini","year":"2010","unstructured":"Mancini T, Porcelli T, Giustina A (2010) Treatment of cushing disease: overview and recent findings. Ther Clin Risk Manag 6:505\u2013516 Epub 20101021. doi: 10.2147\/tcrm.S12952. PubMed PMID: 21063461; PubMed Central PMCID: PMCPMC2963160","journal-title":"Ther Clin Risk Manag"},{"issue":"10","key":"1485_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41574-023-00868-7","volume":"19","author":"M Fleseriu","year":"2023","unstructured":"Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, Langlois F, Melmed S (2023) An individualized approach to the management of cushing disease. Nat Reviews Endocrinol 19(10):581\u2013599. https:\/\/doi.org\/10.1038\/s41574-023-00868-7","journal-title":"Nat Reviews Endocrinol"},{"issue":"4","key":"1485_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing\u2019s Disease. Endocr Rev 36(4):385\u2013486 Epub 20150611. doi: 10.1210\/er.2013-1048. PubMed PMID: 26067718; PubMed Central PMCID: PMCPMC4523083","journal-title":"Endocr Rev"},{"issue":"5","key":"1485_CR24","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11102-023-01345-0","volume":"26","author":"A Giustina","year":"2023","unstructured":"Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P et al (2023) Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers. Pituitary 26(5):583\u2013596 Epub 20230828. https:\/\/doi.org\/10.1007\/s11102-023-01345-0","journal-title":"Pituitary"},{"key":"1485_CR25","doi-asserted-by":"publisher","unstructured":"Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P et al Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE). Pituitary. 2024. Epub 20240604. https:\/\/doi.org\/10.1007\/s11102-024-01397-w. PubMed PMID: 38833044","DOI":"10.1007\/s11102-024-01397-w"},{"issue":"5","key":"1485_CR26","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1210\/jc.2008-0125","volume":"93","author":"LK Nieman","year":"2008","unstructured":"Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM et al (2008) The diagnosis of Cushing\u2019s syndrome: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93(5):1526\u20131540 Epub 20080311. https:\/\/doi.org\/10.1210\/jc.2008-0125","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1485_CR27","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s40618-023-02058-8","volume":"46","author":"R Pivonello","year":"2023","unstructured":"Pivonello R, Scaroni C, Polistena B, Migliore A, Giustina A (2023) Unmet needs on the current medical management of Cushing\u2019s syndrome: results from a Delphi panel of Italian endocrinologists. J Endocrinol Invest 46(9):1923\u20131934 Epub 20230419. https:\/\/doi.org\/10.1007\/s40618-023-02058-8","journal-title":"J Endocrinol Invest"},{"issue":"Supplement1","key":"1485_CR28","doi-asserted-by":"publisher","first-page":"A515","DOI":"10.1210\/jendso\/bvab048.1053","volume":"5","author":"LK Nieman","year":"2021","unstructured":"Nieman LK, Boscaro M, Scaroni CM, Deutschbein T, Mezosi E, Driessens N et al (2021) Metyrapone Treatment in Endogenous Cushing\u2019s syndrome: results at Week 12 from PROMPT, a prospective International Multicenter, Open-Label, phase III\/IV study. J Endocr Soc 5(Supplement1):A515\u2013A. https:\/\/doi.org\/10.1210\/jendso\/bvab048.1053","journal-title":"J Endocr Soc"},{"issue":"1","key":"1485_CR29","doi-asserted-by":"publisher","first-page":"101490","DOI":"10.1016\/j.beem.2021.101490","volume":"35","author":"EV Varlamov","year":"2021","unstructured":"Varlamov EV, Han AJ, Fleseriu M (2021) Updates in adrenal steroidogenesis inhibitors for Cushing\u2019s syndrome - A practical guide. Best Pract Res Clin Endocrinol Metab 35(1):101490 Epub 20210206. https:\/\/doi.org\/10.1016\/j.beem.2021.101490","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"9","key":"1485_CR30","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/s2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A et al (2020) Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8(9):748\u2013761 Epub 20200727. https:\/\/doi.org\/10.1016\/s2213-8587(20)30240-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"1485_CR31","doi-asserted-by":"publisher","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","volume":"107","author":"M Gadelha","year":"2022","unstructured":"Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A et al (2022) Randomized Trial of Osilodrostat for the treatment of Cushing Disease. J Clin Endocrinol Metab 107(7):e2882\u2013e95. https:\/\/doi.org\/10.1210\/clinem\/dgac178PubMed PMID: 35325149; PubMed Central PMCID: PMCPMC9202723","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1485_CR32","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s11102-022-01280-6","volume":"25","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Biller BMK, Bertherat J, Young J, Hatipoglu B, Arnaldi G et al (2022) Long-term efficacy and safety of osilodrostat in Cushing\u2019s disease: final results from a phase II study with an optional extension phase (LINC 2). Pituitary 25(6):959\u2013970 Epub 20221011. https:\/\/doi.org\/10.1007\/s11102-022-01280-6","journal-title":"Pituitary"},{"issue":"6","key":"1485_CR33","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11102-022-01268-2","volume":"25","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Biller BMK (2022) Treatment of Cushing\u2019s syndrome with osilodrostat: practical applications of recent studies with case examples. Pituitary 25(6):795\u2013809 Epub 20220824. doi: 10.1007\/s11102-022-01268-2. PubMed PMID: 36002784; PubMed Central PMCID: PMCPMC9401199","journal-title":"Pituitary"},{"issue":"2","key":"1485_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","volume":"13","author":"L Vilar","year":"2010","unstructured":"Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura ESL et al (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease. Pituitary 13(2):123\u2013129. https:\/\/doi.org\/10.1007\/s11102-009-0209-8PubMed PMID: 19943118","journal-title":"Pituitary"},{"issue":"1","key":"1485_CR35","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G et al (2009) The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223\u2013230 Epub 20081028. https:\/\/doi.org\/10.1210\/jc.2008-1533","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1485_CR36","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1530\/eje-16-0662","volume":"176","author":"A Ferriere","year":"2017","unstructured":"Ferriere A, Cortet C, Chanson P, Delemer B, Caron P, Chabre O et al (2017) Cabergoline for Cushing\u2019s disease: a large retrospective multicenter study. Eur J Endocrinol 176(3):305\u2013314 Epub 20161222. https:\/\/doi.org\/10.1530\/eje-16-0662","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"1485_CR37","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1210\/jc.2009-1311","volume":"94","author":"A Ben-Shlomo","year":"2009","unstructured":"Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V et al (2009) Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab 94(11):4342\u20134350 Epub 20091009. https:\/\/doi.org\/10.1210\/jc.2009-1311","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1485_CR38","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M et al (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366(10):914\u2013924 doi: 10.1056\/NEJMoa1105743. PubMed PMID: 22397653","journal-title":"N Engl J Med"},{"issue":"12","key":"1485_CR39","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM et al (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 65(12):1925\u20131966. https:\/\/doi.org\/10.1007\/s00125-022-05787-2","journal-title":"Diabetologia"},{"issue":"2","key":"1485_CR40","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","volume":"17","author":"A Colao","year":"2014","unstructured":"Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF (2014) Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations. Pituitary 17(2):180\u2013186. https:\/\/doi.org\/10.1007\/s11102-013-0483-3","journal-title":"Pituitary"},{"issue":"5","key":"1485_CR41","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s11102-014-0618-1","volume":"18","author":"J Schopohl","year":"2015","unstructured":"Schopohl J, Gu F, Rubens R, Van Gaal L, Bertherat J, Ligueros-Saylan M et al (2015) Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing\u2019s disease: results from an open-ended, open-label extension trial. Pituitary 18(5):604\u2013612. https:\/\/doi.org\/10.1007\/s11102-014-0618-1PubMed PMID: 25537481; PubMed Central PMCID: PMCPMC4560758","journal-title":"Pituitary"},{"issue":"3","key":"1485_CR42","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s12020-018-1818-7","volume":"64","author":"R Pivonello","year":"2019","unstructured":"Pivonello R, Arnaldi G, Scaroni C, Giordano C, Cannav\u00f2 S, Iacuaniello D et al (2019) The medical treatment with pasireotide in Cushing\u2019s disease: an Italian multicentre experience based on real-world evidence. Endocrine 64(3):657\u2013672 Epub 20190409. https:\/\/doi.org\/10.1007\/s12020-018-1818-7","journal-title":"Endocrine"},{"issue":"1","key":"1485_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s2213-8587(17)30326-1","volume":"6","author":"A Lacroix","year":"2018","unstructured":"Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P et al (2018) Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 6(1):17\u201326 Epub 20171012. https:\/\/doi.org\/10.1016\/s2213-8587(17)30326-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1485_CR44","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/cen.14081","volume":"91","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu M, Petersenn S, Biller BMK, Kadioglu P, De Block C, T\u2019Sjoen G et al (2019) Long-term efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a phase III extension study. Clin Endocrinol (Oxf) 91(6):776\u2013785 Epub 20191001. https:\/\/doi.org\/10.1111\/cen.14081","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1485_CR45","doi-asserted-by":"publisher","first-page":"1165681","DOI":"10.3389\/fendo.2023.1165681","volume":"14","author":"RA Feelders","year":"2023","unstructured":"Feelders RA, Fleseriu M, Kadioglu P, Bex M, Gonz\u00e1lez-Devia D, Boguszewski CL et al (2023) Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing\u2019s disease. Front Endocrinol (Lausanne) 14:1165681 Epub 20231009. https:\/\/doi.org\/10.3389\/fendo.2023.1165681","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1485_CR46","doi-asserted-by":"publisher","unstructured":"Grottoli S, Maffei P, Tresoldi AS, Granato S, Benedan L, Mariani P et al (2024) Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management. J Endocrinol Invest. Epub 20240529. https:\/\/doi.org\/10.1007\/s40618-024-02386-3. PubMed PMID: 38809458","DOI":"10.1007\/s40618-024-02386-3"},{"issue":"12","key":"1485_CR47","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1080\/14656566.2016.1199687","volume":"17","author":"F Maffezzoni","year":"2016","unstructured":"Maffezzoni F, Formenti AM, Mazziotti G, Frara S, Giustina A (2016) Current and future medical treatments for patients with acromegaly. Expert Opin Pharmacother 17(12):1631\u20131642 Epub 20160628. https:\/\/doi.org\/10.1080\/14656566.2016.1199687","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"1485_CR48","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 97(6):2039\u20132049 Epub 20120330. https:\/\/doi.org\/10.1210\/jc.2011-3350","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1485_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11102-013-0475-3","volume":"17","author":"M Barbot","year":"2014","unstructured":"Barbot M, Albiger N, Ceccato F, Zilio M, Frigo AC, Denaro L et al (2014) Combination therapy for Cushing\u2019s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole? Pituitary 17(2):109\u2013117. https:\/\/doi.org\/10.1007\/s11102-013-0475-3PubMed PMID: 23468128","journal-title":"Pituitary"},{"issue":"19","key":"1485_CR50","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR et al (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N Engl J Med 362(19):1846\u20131848. https:\/\/doi.org\/10.1056\/NEJMc1000094PubMed PMID: 20463350","journal-title":"N Engl J Med"},{"issue":"9","key":"1485_CR51","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1210\/jc.2011-0536","volume":"96","author":"P Kamenick\u00fd","year":"2011","unstructured":"Kamenick\u00fd P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier JF et al (2011) Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s syndrome. J Clin Endocrinol Metab 96(9):2796\u20132804 Epub 20110713. https:\/\/doi.org\/10.1210\/jc.2011-0536","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01485-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-024-01485-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-024-01485-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T14:33:11Z","timestamp":1741444391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-024-01485-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1485"],"URL":"https:\/\/doi.org\/10.1007\/s11102-024-01485-x","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"27 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Giustina is the editor-in-chief in Pituitary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}